Showing 2952 results
-
Press release /Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)…
-
Press release /NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…
-
Media Library / -
Media Library / -
Story /Novartis partners with the Special Olympics to support neuro‑inclusion and build environments where everyone belongs.
-
Story /Polly Cooper, Clinical Development Function Head, UK
-
Event /Novartis will announce the company’s financial results for the third quarter of 2026.
-
Statement /